Back to search
FDAFDA · Food and drugs·Recall number D-0701-2022

Diflorasone Diacetate Ointment USP, 0.05%, Net Wt 60 g tubes, Rx only, Manufactured by: Teligent Pharm, Inc., Buena, New Jersey 08310, NDC 52565-063-60.

Published March 30, 2022 · Recall initiated: March 15, 2022

Summary

FDA records drug Class II recall D-0701-2022, published March 30, 2022 and initiated March 15, 2022. Recalling firm: Teligent Pharma, Inc.; Status: Terminated; Reported quantity: 4532 tubes; Lot: Batch: 15876, Exp 8/31/2022; 16205, Exp. 11/30/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teligent Pharma, Inc.
Distributor
Nationwide in the USA and Puerto Rico
Lot
Batch: 15876, Exp 8/31/2022; 16205, Exp. 11/30/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Diflorasone Diacetate Ointment USP, 0.05%, Net Wt 60 g tubes, Rx only, Manufactured by: Teligent Pharm, Inc., Buena, New Jersey 08310, NDC 52565-063-60. recalled?

Yes. FDA published recall D-0701-2022 on March 30, 2022. Reported hazard: cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

What should I do if I have this product?

Voluntary: Firm initiated · Letter